Perrigo Company Showcases Consumer Health Commitment at Upcoming UBS Conference
- Perrigo Company plc will showcase its consumer health commitment at the UBS Global Consumer and Retail Conference on March 11, 2026.
- The company offers a wide range of OTC self-care products, integrating private-label offerings with renowned brands like Opill® and Mederma®.
- Perrigo emphasizes transparency and stakeholder engagement as part of its disciplined corporate governance and commitment to consumer wellness.
Perrigo Company Strengthens Commitment to Consumer Health at Upcoming Conference
Perrigo Company plc, a leading global consumer health provider, prepares to showcase its dedication to enhancing wellness solutions at the UBS Global Consumer and Retail Conference scheduled for March 11, 2026. President and CEO Patrick Lockwood-Taylor will present insights into Perrigo’s strategic direction at 11:00 AM EDT, with an accompanying webcast available on the company’s investor website. This presentation serves as an opportunity for the company to highlight its extensive portfolio of over-the-counter (OTC) self-care products, which have been a cornerstone of its operations for more than a century.
With a focus on consumer health, Perrigo operates a robust business model that integrates private-label offerings alongside established brands. The company’s product suite features renowned names such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®, granting consumers access to a myriad of non-prescription health solutions across North America and Europe. By effectively blending high-quality private labels with well-known brands, Perrigo enhances its competitive positioning in the consumer health market. This approach not only fosters customer trust but also encourages higher consumer choice, essential in the growing demand for self-care products.
The company's forward-looking statements included in their recent press release acknowledge the potential risks and uncertainties that may impact its future performance. Perrigo encourages stakeholders and investors to consider these risk factors, as outlined in its Form 10-K for the fiscal year ending December 31, 2025. This attention to transparency reflects a disciplined approach to corporate governance and risk management, crucial for navigating the ever-evolving landscape of consumer health. Interested parties can access further details on Perrigo's business and financial condition through their filings with the United States Securities and Exchange Commission and via their official website.
In addition to the upcoming conference, Perrigo emphasizes its commitment to consumer-centric health and wellness solutions. This focus underpins its operational strategies, ensuring that the company continues to meet the health needs of its customers effectively. For those looking for more comprehensive information on the company’s evolving product offerings and health initiatives, Perrigo's Global Investor Relations team stands available for inquiries, highlighting an ongoing dedication to engagement and transparency with stakeholders.
Related Cashu News

Travere Therapeutics Reports Positive FILSPARI Results and Achieves First Profitable Quarter
Travere Therapeutics (Ticker: TVTX) shows promising advancements in its drug FILSPARI, vital in treating focal segmental glomerulosclerosis (FSGS). Recently, the company released positive long-term da…

PTC Therapeutics Raises $500 Million for Debt Management and Growth in Biopharmaceuticals
PTC Therapeutics (Ticker: PTCT) aims to strengthen its financial position through a recent private placement of $500 million in Convertible Senior Notes due in 2031. This strategic move is intended to…

Insmed Navigates Investor Changes Amid Strong Pipeline and Mixed Analyst Sentiment
Insmed Inc (Ticker: INSM) is in a transformative phase as it navigates recent changes in its investor landscape and the impact on its business model. The company, known for its focus on rare diseases,…

Atossa Therapeutics Raises $4.5 Million to Support Oncology Clinical Development Efforts
Atossa Therapeutics (Ticker: ATOS) successfully finalizes a registered direct offering, generating approximately $4.5 million. This funding is crucial as the company progresses its clinical efforts ai…